Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC

The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing authorization from the European Commission, following a positive review from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

April 21 (Reuters) - Moderna said on Tuesday the European Commission had approved its combination vaccine for the prevention of influenza and COVID-19 in adults 50 years of age and older. Here are the details: • The approval follows a positive recommendation from the European Medicines Agency,

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines.

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

April 21 (Reuters) - Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the U.S. and the UK, marking the first time a pandemic bird flu vaccine made with mRNA technology has reached late-stage trials.

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted